GREY:IPHAF - Post by User
Post by
go4futureon Sep 23, 2009 8:34am
410 Views
Post# 16330496
Lux Phase 1 Dry Eye (LX214) Safety Results
Lux Phase 1 Dry Eye (LX214) Safety ResultsLux has posted positive safety and open-label efficacy results for the Phase 1 LX214 human study. Lux views LX214 as the crown jewel in their pipeline.
https://www.luxbio.com/pr092309.htm
An Ophthalmic Pharmaceutical Report was also published on Sept 21 outlining the market outlook and also includes LUVENIQ.
https://www.reportlinker.com/p0148144/Reportlinker-Adds-The-Ophthalmic-Pharmaceutical-Market-Outlook-To-2014-Competitive-landscape-pipeline-analysis-growth-opportunities-and-market-forecasts.html